



Express Mail No.: EQ 238 068 436 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young *et al.*

Confirmation No.: 7010

Application No.: 09/724,531

Group Art Unit: 1648

Filed: November 28, 2000

Examiner: Stacy Brown Chen

For: METHODS OF ADMINISTERING/
DOSING ANTI-RSV ANTIBODIES
FOR PROPHYLAXIS AND
TREATMENT

Attorney Docket No.: 10271-021-999
(CAM: 209073-020999)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the **C24** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." A copy of reference **C24** is submitted herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of "List of Prior Art Cited."

Applicants respectfully request that the Examiner review the foregoing reference and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), Applicants estimate that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 503013. A duplicate of this sheet is enclosed for accounting purposes.

Date: Nov. 21, 2006

Respectfully submitted,
Tamera M. Pertmer
For: Anthony M. Insogna


Tamera M. Pertmer, Ph.D. (Reg. No. 47,856)
JONES DAY
12750 High Bluff Drive, Suite 300
San Diego, CA 92130
(858) 314-1181

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, NY 10017
(212) 326-3939

Enclosures

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY. DOCKET NO.

10271-021-999

APPLICATION NO.

09/724,531

APPLICANT

Young et al.

FILING DATE

November 28, 2000

ART UNIT

1648

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01				
	A02				
	A03				

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01					
	B02					
	B03					
	B04					
	B05					

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C24	The IMpact-RSV Study Group, "Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants." Pediatrics. 1998 Sep;102(3 Pt 1):531-537	
	C25		
	C26		
	C27		
	C28		
	C29		
	C30		
	C31		
	C32		
	C33		
	C34		
	C35		

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.